#### Check for updates

#### **OPEN ACCESS**

EDITED BY Jean-Paul Motta, INSERM U1220 Institut de Recherche en Santé Digestive, France

REVIEWED BY Gajanan Katkar, University of California, San Diego, United States Žiga Jakopin, University of Ljubljana, Slovenia

\*CORRESPONDENCE Thomas A. Kufer ⊠ thomas.kufer@uni-hohenheim.de

RECEIVED 11 April 2025 ACCEPTED 06 June 2025 PUBLISHED 25 June 2025

#### CITATION

Biber L, Schart N, Bosy-Westphal A and Kufer TA (2025) A sensitive bioassay to measure NOD1/2 ligands in human serum reveals differential postprandial NOD2 activation. *Front. Nutr.* 12:1596951.

doi: 10.3389/fnut.2025.1596951

#### COPYRIGHT

© 2025 Biber, Schart, Bosy-Westphal and Kufer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## A sensitive bioassay to measure NOD1/2 ligands in human serum reveals differential postprandial NOD2 activation

Lucy Biber<sup>1</sup>, Nadine Schart<sup>1</sup>, Anja Bosy-Westphal<sup>2</sup> and Thomas A. Kufer<sup>1</sup>\*

<sup>1</sup>Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany, <sup>2</sup>Institute of Human Nutrition and Food Science, Kiel University, Kiel, Germany

Food intake is associated with the occurrence of components and metabolites from the gut microbiota in the bloodstream. Using a widely utilised cell-based assay to measure bacterial peptidoglycan via pattern-recognition receptor activation, we found that the performance of this assay is significantly influenced by the presence of other serum components. To address this challenge, an alternative luciferase-based reporter assay protocol was established to accurately measure NOD1 and NOD2 activation by serum samples with high sensitivity. Utilising postprandial human serum samples, we tested this assay and showed that the concentration of NOD2-activating ligands differed in the postprandial phase. Together, we provide a protocol to measure NOD1/2 activation by human serum samples and highlight a role for NOD2 in the postprandial response.

#### KEYWORDS

reporter gene assay, NLR, peptidoglycan, food intake, immune response, innate immunity, SEAP

## Introduction

The intricate interplay between nutrition and the gut microbiota has emerged as a critical area of research, particularly in elucidating how dietary components influence microbial composition and function, as well as their systemic effects on human health (1). Within the immune system, nucleotide binding oligomerization domain containing 1 (NOD1) and nucleotide binding oligomerization domain containing 2 (NOD2) are pivotal pattern recognition receptors (PRRs) that detect bacterial components and initiate innate immune responses. NOD1 is primarily activated by  $\gamma$ -D-glutamyl-meso-diaminopimelic acid (iE-DAP), a peptidoglycan fragment found predominately in Gram-negative bacteria, while NOD2 recognizes muramyl dipeptide (MDP), a conserved motif found in the peptidoglycan structure of both Gram-positive and Gram-negative bacteria (2). Upon ligand recognition, these receptors activate downstream signaling pathways, including nuclear factor kappa B (NF- $\kappa$ B) and mitogen-activated protein kinases (MAPKs), leading to the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides. These responses are essential for host defense against microbial infections and play a crucial role in maintaining gut homeostasis (3).

Dysregulation of NOD1 and NOD2 signaling has been implicated in inflammatory bowel diseases (IBD), metabolic syndrome, and other immune-related disorders (4). Notably, diet has a profound impact on immune function, both long lasting and at early time points through a process termed postprandial inflammation. Following food intake, transient absorption of dietary components such as lipids and carbohydrates triggers low-grade inflammation characterized by elevated serum levels of interleukin-6 (IL-6) (5). This postprandial response has been associated

with an increased risk of chronic diseases such as cardiovascular disease and insulin resistance (6). The mechanisms underlying postprandial inflammation are discussed to be multifactorial and seem to involve interactions between dietary components and the gut microbiota. Translocation of microbial-associated molecular patterns (MAMPs), including lipopolysaccharides (LPS) and peptidoglycan fragments, into systemic circulation is one possible cause of this inflammatory response. Some members of the NLR-family of proteins, including NOD1 and NOD2 have been shown to contribute to the postprandial inflammatory milieu, and can contribute to exacerbate inflammation and to metabolic complications like insulin resistance (7, 8).

To investigate physiological activation of NOD1 and NOD2, cellbased reporter assays have become indispensable tools. These assays typically utilize cell lines transfected with plasmids encoding NOD1 or NOD2 to measure receptor activation upon exposure to specific ligands. Two widely used methods are the secreted embryonic alkaline phosphatase (SEAP) assay and the luciferase reporter assay. The SEAP assay quantifies alkaline phosphatase activity secreted into the medium under promoter control responsive to NOD signaling pathways like NF- $\kappa$ B (9). In the luciferase reporter assay, light emission catalyzed by luciferase under similar promoter control is used as readout, offering high sensitivity suitable for high-throughput applications (10).

In this study, we provide evidence that SEAP-based reporter assays are not well suited for measuring serum NOD1/2 ligands. To overcome these limitations, we established a protocol for an optimized luciferase-based reporter assay to measure NOD1 and NOD2 activation by bioactive bacterial peptidoglycan in human serum samples. Validation experiments confirmed good correlations between luminescence signals and concentrations of known ligands for these receptors. By examining fluctuations in NOD2 activation by serum in response to dietary intake our findings provide novel insights into how nutrition modulates immune function in humans.

## Methods

### Human serum samples

Human serum from eight participants of the meal skipping study (11), which has been stored at  $-80^{\circ}$ C, was used. In brief, blood was drawn before (0 h) and 0.5 h, 1 h, 1.5 h, 2 h, and 4 h after lunch following a normal breakfast (from the dinner skipping day) or skipped breakfast (S1–S8). The study protocol was approved by the ethics committee of the Medical Council of Baden-Württemberg, Germany. The trial is registered at clinicaltrials.gov as NCT02635139. For establishment of the assays, human sera from three healthy individuals were used, which was approved by the ethics committee of the University of Hohenheim (09.06.2021). Studies were conducted in accordance with the Declaration of Helsinki and all participants provided written informed consent before participation.

## SEAP-based HEK-Blue NF-κB reporter assay

Per well,  $5 \times 10^4$  HEK-Blue<sup>TM</sup> hNOD1 or HEK-Blue<sup>TM</sup> hNOD2 cells (InvivoGen) were seeded in 90 µL DMEM (Gibco, Thermo Fisher Scientific) with 10% heat treated (20 min at 56°C) FBS Xtra

(Capricorn) in an F-bottom 96-well plate (Greiner Bio-One). Cells were stimulated with 10  $\mu$ L human serum, DMEM as unstimulated control or the indicated concentration of MDP (tlrl-mdp, InvivoGen) and TriDAP (tlrl-tdap, InvivoGen). After 16 h at 37°C with 5% CO2 in a humid atmosphere, 20  $\mu$ L of the supernatant was added to 180  $\mu$ L QUANTI-Blue<sup>TM</sup> solution (InvivoGen). Absorbance at 620 nm was measured photometrically (EnSpire, Perkin Elmer) after 7 h at 37°C and normalized to the absorbance of unstimulated cells to calculate relative NF- $\kappa$ B activity. Cells were maintained in the presence of 30  $\mu$ g/mL blasticidin (Invivogen) and 100  $\mu$ g/mL Zeocin (Invivogen).

To test for alkaline phosphatase activity in human serum samples, 20  $\mu$ L of serum was incubated with 180  $\mu$ L QUANTI-Blue solution and measured after 2 h at 37°C with the same settings as described above.

### NF-κB luciferase reporter assay

NF-κB luciferase reporter assays were performed as described in Zurek et al. (10). In brief  $3 \times 10^4$  HEK293T cells were seeded in 50 µL DMEM with 10% FBS and 20 µL DMEM per well in an F-bottom 96-well plate and incubated for 1 h at 37°C with 5% CO<sub>2</sub> in a humid atmosphere. For transfection, plasmids in 20 µL OptiMEM (Gibco, Thermo Fisher Scientific) were incubated with 0.17 µL XtremeGene9 (Roche) for 20 min at room temperature. Per well, plasmid mixture consisted of: 13 ng luciferase under an NF-κB promoter, 8.6 ng constitutively expressed β-galactosidase and when indicated 0.25 ng NOD1 or 0.05 ng NOD2, ad 51 ng pcDNA.

Directly or, if not indicated elsewise, 10 h after transfection for serum stimulation experiments, cells were stimulated with indicated concentrations of MDP, TriDAP or human serum. DMEM served as unstimulated control. Readout was performed 16 h or 14 h after stimulation for serum experiments as described in Zurek et al. (10) and Kuri et al. (12). In brief, cells were lysed and luciferase activity as a readout for NF- $\kappa$ B activity (RLU) and  $\beta$ -galactosidase activity were measured. If not stated otherwise, NF- $\kappa$ B activity was normalized to  $\beta$ -galactosidase signal (nRLU). Relative NF- $\kappa$ B activity was calculated by the ratio of the normalized stimulated to the normalized unstimulated cell NF- $\kappa$ B activity.

### Statistics

Statistic analysis was performed with Python 3 (Python Software Foundation) and the help of scipy and scikit-posthocs packages. To analyze postprandial differences in NOD1/NOD2 ligands, the Kruskal–Wallis test was used, followed by Dunn's test if significant. Data is presented as mean with standard error of mean (SEM). *p*-values below 0.05 were considered statistically significant.

## Results

# Functionality of SEAP-based cellular bioassay for measurements of human serum samples

Commercially available reporter cell lines for human NOD1 and NOD2 (HEK-Blue cell lines; InvivoGen) testing stably express the

human PRR NOD1 or NOD2 and a SEAP reporter under control of the NF- $\kappa$ B promotor. Upon ligand recognition, NOD1 and NOD2 are activated and induce activation of the transcription factor NF- $\kappa$ B, resulting in the transcription and secretion of SEAP in the supernatant, which can subsequently be detected by the SEAP detection reagent QUANTI-Blue (InvivoGen).

This assay is frequently used, most recently in a study showing that in mice, a high-fat diet led to an increase in NOD1 ligands in the serum (13). Here, we tested human serum of eight participants of the meal skipping study (11) using the human NOD1 and NOD2 HEK-Blue cell lines. For both PRRs, we observed consistent differences between the individuals (Figure 1A). As human serum contains alkaline phosphatase (AP) (14), we wondered if the human enzyme could catalyze the detection reagent as well. To this end, we incubated the serum with the detection reagent and observed a similar activation pattern (Figure 1B), which showed a high correlation (squared Pearson correlation coefficient of 0.86 for NOD1 and 0.91 for NOD2) with the measured NF- $\kappa$ B activation of the NOD1 and NOD2 cell lines (Figure 1C). This showed that the

measured signal in the reporter assay is likely explained by different AP concentrations in the serum samples rather than by differences in NOD1/2 agonists. This shows, that a SEAP-based reporter system is not well suited to detect PRR activity induced by serum from humans.

### Development of a protocol for a robust luciferase-based reporter assay to measure NOD1 and NOD2 activation in human serum samples

To overcome these limitations, we switched to the widely used luciferase reporter-gene assay (10, 12). This system relies on transient transfection of human HEK293T cells with a luciferase reporter plasmid under the control of a strong NF- $\kappa$ B-inducible promotor, a constitutively active  $\beta$ -galactosidase expression plasmid and expression plasmids encoding the PRR of interest (Figure 2A upper panel). To compare this assay with the HEK-blue assay, TriDAP and MDP were titrated in the NOD1 and NOD2



#### FIGURE 1

Characterization of SEAP-based HEK-blue assays to measure NOD1 and NOD2 activation in serum samples. (A) NF- $\kappa$ B activation potential of human serum (S1 to S8) 1.5 h after lunch on the breakfast-skipping day was measured with HEK-Blue NOD1 and HEK-Blue NOD2 cells. The signal was normalized to unstimulated cells. (B) Alkaline phosphatase activity was determined by incubating human serum with QUANTI-Blue detection solution and normalization to QUANTI-Blue signal alone. (C) Linear regression of NOD1/NOD2 HEK-Blue cell measured NF- $\kappa$ B activation potential and alkaline phosphatase activity of human serum. 95% confidence interval and squared Pearson correlation coefficient are shown. Two independent experiments were performed. Dots represent mean of technical triplicates for each experiment and bars represent mean and SEM of both runs together.



FIGURE 2

Characterization of an optimized protocol for an NF-κB luciferase reporter assay. (A) Schematic overview of the luciferase and HEK-Blue NF-κB reporter assay. (B) HEK-Blue NOD1/NOD2 cells or HEK293T cells transfected with the NOD1/NOD2 luciferase reporter system were stimulated with increasing concentrations of TriDAP or MDP, respectively. NF-κB signal was normalized to unstimulated cells. Dashed line represents unstimulated

(Continued)

#### FIGURE 2 (Continued)

cells. Graphs show mean and SEM of two independent experiments performed in technical triplicates. **(C,D)** NOD1 and NOD2 luciferase reporter assays were stimulated directly after transfection with different amounts of two different human sera, indicated as dots, and 20 nM TriDAP (T) or 10 nM MDP (M) as positive control. **(C)** Shows measured luciferase signal for NF- $\kappa$ B activation and **(D)**  $\beta$ -galactosidase activity as transfection control. **(E)** NOD1 and NOD2 luciferase reporter assay was performed with stimulation 5 h, 7 h, 10 h, and 24 h after transfection. (Left)  $\beta$ -galactosidase signal of serum stimulated cells was normalized to  $\beta$ -galactosidase signal of unstimulated cells of the same plasmid type and posttransfection time point. (Middle) Raw NF- $\kappa$ B activity of unstimulated cells is depicted. (Right) NOD1 and NOD2 transfected cells were stimulated with 40 nM TriDAP or 20 nM MDP, respectively. Ligand stimulated NF- $\kappa$ B activity was normalized to NF- $\kappa$ B activity of unstimulated cells. Bars represent mean and SEM of technical triplicates from one experiment.

transfected cells, respectively. As expected, both assays showed a dose-dependent response towards the respective ligand, however the luciferase reporter assay turned out to be more sensitive. The NOD1 luciferase reporter assay already detected 25 nM TriDAP, whereas the HEK-blue NOD1 cell line only showed a slight increase in NF- $\kappa$ B-activity with 400 nM TriDAP (Figure 2B).

Next, we added different amounts of human serum to the NOD1 and NOD2 transfected cells. Already using 4% of serum thereby led to complete block of basal luciferase activity (Figure 2C). In line, no β-galactosidase activity was detected in the serum treated samples Figure 2D. This suggested that the serum either interfered with the enzymatic detection or the transfection procedure. To clarify this, serum was added 5 h, 7 h, 10 h, and 24 h after transfection, respectively. The β-galactosidase activity of the serum stimulated cells increased with longer incubation periods between transfection and serum stimulation (Figure 2E left panel). On the other hand, we observed an increased auto-activity of both PRRs with increased transfection times, depicted by increased luciferase (NF-KB)-activity of the unstimulated cells (Figure 2E middle panel). The RLU values obtained with the 24 h transfection reached the detection limit, impairing interpretation of NF- $\kappa$ B activation by potential NOD1/2 agonists. The  $\beta$ -galactosidase activity, representing a proxy for transfection efficacy and cell viability, was very low up to 7 h posttransfection but increased after 10 h and 24 h of incubation. With the 10 h incubation time we could obtain a good compromise between robustness and sensitivity of the assay, showing for NOD2 a 1.4-fold higher sensitivity compared to 5 h (Figure 2E right panel). We thus decided to use a 10 h incubation period for further assays.

## Sensitivity of the assay and freeze-thaw effect

To identify the lower detection limit of our modified luciferasereporter assay, we stimulated NOD1 and NOD2 transfected cells with serum samples spiked with different concentrations of TriDAP and MDP. With both NOD1 and NOD2, we observed a dose dependent NF- $\kappa$ B response towards their respective ligand and the spiked serum samples. For the NOD1 luciferase-reporter assay, we observed a robust NF- $\kappa$ B activity increase with 7.5 nM TriDAP and serum spiked with 7.5 nM TriDAP (Figure 3A, left panel). The NOD2 assay detected already 1.25 nM MDP in medium and 10 nM MDP in serum (Figure 3A, right panel).

Samples from human subjects and from intervention studies are limited material and are typically stored frozen. To find out if freezing and thawing affected the bioactivity of TriDAP and MDP in serum, we froze spiked serum samples and diluted TriDAP and MDP in DMEM at  $-80^{\circ}$ C for 3 days and repeated the assay. Surprisingly, we observed a slight increase in activity of the serum spiked with TriDAP (Figure 3B left panel), but no difference for the MDP spiked

serum. MDP seems to be even stabilized by serum during freezethaw, as the NOD2 reactivity of the pure MDP dilutions was lower in the stored samples (Figure 3B, right panel).

Taken together, we could establish sensitive assays to measure NOD1 and NOD2 activity down to the low nM range of bacterial peptidoglycan. Our results show that freezing does not negatively affect NOD1/2 ligand activity in serum samples.

## Analysis of NOD1 and NOD2 activity in serum samples from a postprandial cohort

In order to evaluate our new assay protocol for detection of bacterial peptidoglycan in human serum samples, we used a series of serum samples from eight participants of the meal skipping study from Nas et al. (11). In this controlled intervention study, serum was taken before (0 h) and 0.5 h, 1 h, 2 h and 4 h after food intake. The study used lunchtime for the food challenge and a two-arm design including either a short (normal breakfast) or longer (breakfast skipping) fasting period directly before lunch (Figure 4A). Our results showed that NOD2 ligands increased in the serum of the participants already 0.5 h or 1 h after the food intake, compared to the preprandial condition (0 h) and peaked at 1 h or 2 h for skipped (Figure 4B, right panel) or normal breakfast sera (Figure 4C, right panel), respectively. A decline in the NOD2 reactivity was observed at the 4 h timepoint. Interestingly, the NOD1 and NOD2 signal of the normal breakfast serum decreased even below the preprandial level, whereas the breakfast skipped samples only showed reduction to about the levels measured at the 1 h timepoint (Figures 4B,C right panel). For NOD1 assay, interindividual differences were observed, however overall no clear trend or significant changes upon food intake were obtained (Figures 4B,C left panel).

To summarize, this shows that NOD2 ligands significantly change in the serum upon food intake and that fasting affects this kinetic.

## Discussion

Here we show that SEAP-based cell assays are not suitable for analysis of human serum, as the AP activity in the serum significantly affects the read-out (Figure 1). AP levels differ between individuals depending on age, sex, diseases or medication (14). In humans, AP levels are discussed as a marker for low-grade inflammation (15) and multiple diseases like the metabolic syndrome (16, 17). Additionally, individual AP serum levels can vary over the day, as they are decreased in a fasted state and increase 2 to 3 h after fat intake (18, 19), which further complicates the use of SEAP-based reporters in the context of postprandial reactions or metabolic diseases. This also applies to other mammalian species, namely mice (20). In some recent publications, such assays were used to show an increase in various systemic PRR ligands in



high-fat diet fed mice (13) and as markers for small intestine barrier function in mice (21, 22) and men (22). To avoid that bias, only one study used heat treated (75°C for 5 min) serum, which inactivates AP activity. Using this serum, the authors observed an increase in TLR4, but not NOD2 ligands in mice with obesity (23). In other studies, this issue was not considered. In future works such shortcomings should be better addressed.

We propose that the assay protocol established here provides a suited and robust way to assay activity of NOD1 and NOD2 ligands in serum samples. This is corroborated by the validation of this protocol by spiked serum samples and in a serum sample cohort.

Moreover, in postprandial serum samples of the meal skipping cohort (11), we observed a postprandial increase of NOD2 ligands after lunch (Figure 4). As both PRRs are activated by peptidoglycan fragments that enter the circulation passively, we suspect that our NOD1 assay with a detection limit around 7.5 nM TriDAP might not be sensitive enough to detect the slight postprandial increase, beside potential biological differences between NOD1 and NOD2 ligand concentration in the serum. Another explanation could be that not only bacterial fragments but other molecules like dietary-specific fatty acids might be able to activate NOD2 after food intake (24, 25).

Interestingly, we observed a greater and faster increase of NOD2 ligands in the serum of the 18 h fasted participants (breakfast skipping day) compared to the 6 h fasted individuals (normal breakfast day) (Figure 4). It might be that fasting increases gut permeability, which was reported previously in mice (26) and rats (27). In the meal skipping study (11), the 18 h fasted participants showed higher variances in the postprandial response. Blood from breakfast skipping individuals showed phytohemagglutinin (PHA) induced IL-6 release that was significantly decreased below preprandial levels at 30 min and increased above preprandial levels 4 h postprandial (11). This may indicate an increased postprandial inflammation, which could be related to the elevated NOD2 ligands. However, additional cohorts, also using different meal intervention, should be tested to establish if this is a general mechanism.



On the other hand, NOD2 signaling was shown to be important for the functionality of the metabolism and to be protective against metabolic diseases like diabetes (7). In addition, NOD2 activating peptidoglycans in the circulation lowered blood glucose and reduced low grade inflammation in HFD fed mice. At the same time, an injection of NOD1 activating ligands reduced glucose tolerance (28). To this end, the postprandial increase of NOD2 ligands could also help the organism deal with the sudden increase of nutrients in the blood. Our results provide the basis to use this protocol for the analysis of serum samples and underlines a critical role of NOD2 ligands and NOD2 in the postprandial response.

## Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

## **Ethics statement**

The studies involving humans were approved by Ethics Committee of the Medical Council of Baden-Württemberg, NCT02635139. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

## Author contributions

LB: Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. NS: Investigation, Validation, Writing – review & editing. AB-W: Methodology, Resources, Writing – review & editing. TK: Conceptualization, Funding acquisition, Resources, Supervision, Writing – original draft, Writing – review & editing.

## Funding

The author(s) declare that financial support was received for the research and/or publication of this article. Publishing fees supported by Funding Programme Open Access Publishing of University of Hohenheim. This work was funded by the EU-HDHL NUTRIMMUNE 2022 Project RESIST-PP (DLR 01EA2301).

## References

1. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med.* (2020) 26:964–73. doi: 10.1038/s41591-020-0934-0

2. Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. *Immunity*. (2014) 41:898–908. doi: 10.1016/j.immuni.2014.12.010

3. Claes AK, Zhou JY, Philpott DJ. NOD-like receptors: guardians of intestinal mucosal barriers. *Physiology*. (2015) 30:241–50. doi: 10.1152/physiol.00025.2014

4. Trindade BC, Chen GY. NOD1 and NOD2 in inflammatory and infectious diseases. Immunol Rev. (2020) 297:139-61. doi: 10.1111/imr.12902

5. Emerson SR, Kurti SP, Harms CA, Haub MD, Melgarejo T, Logan C, et al. Magnitude and timing of the postprandial inflammatory response to a high-fat meal in healthy adults: a systematic review. *Adv Nutr.* (2017) 8:213–25. doi: 10.3945/an.116.014431

6. Sasso E, Baticic L, Sotosek V. Postprandial dysmetabolism and its medical implications. *Life*. (2023) 13:2317. doi: 10.3390/life13122317

7. Bauer S, Hezinger L, Rexhepi F, Ramanathan S, Kufer TA. NOD-like receptorsemerging links to obesity and associated morbidities. *Int J Mol Sci.* (2023) 24:8595. doi: 10.3390/ijms24108595

8. Rodrigues ELR, Fang H, Robin N, Bhatwa A, Marko DM, Schertzer JD. Microbiota and nod-like receptors balance inflammation and metabolism during obesity and diabetes. *Biom J.* (2023) 46:100610. doi: 10.1016/j.bj.2023.100610

9. Wang M, Wang X, Ye H. Measurement of secreted embryonic alkaline phosphatase. *Bio Protoc*. (2023) 13:e4600. doi: 10.21769/BioProtoc.4600

## Acknowledgments

The authors thank Yvonne Postma for perfect technical assistance in performing the assays, Dr. Timo Voß for support with statistical analysis and Felix Biber for help with data processing. The authors thank Dr. Maharajah Ponnaiah (ICAN I/O—Data Science, IHU ICAN, Pitié-Salpêtrière Hospital, Paris) for his support in validating the statistical analysis. The authors thank all consortium members for helpful discussion of this work.

## **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

## **Generative AI statement**

The authors declare that no Gen AI was used in the creation of this manuscript.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10. Zurek B, Bielig H, Kufer TA. Cell-based reporter assay to analyze activation of Nod1 and Nod2. Methods MolBiol. (2011) 748:107–19. doi: 10.1007/978-1-61779-139-0\_7

11. Nas A, Mirza N, Hagele F, Kahlhofer J, Keller J, Rising R, et al. Impact of breakfast skipping compared with dinner skipping on regulation of energy balance and metabolic risk. *Am J Clin Nutr.* (2017) 105:1351–61. doi: 10.3945/ajcn.116.151332

12. Kuri P, Ellwanger K, Kufer TA, Leptin M, Bajoghli B. A high-sensitivity bidirectional reporter to monitor NF- $\kappa$ B activity in cell culture and zebrafish in real time. *J Cell Sci.* (2017) 130:648–57. doi: 10.1242/jcs.196485

13. Chan KL, Tam TH, Boroumand P, Prescott D, Costford SR, Escalante NK, et al. Circulating NOD1 activators and hematopoietic NOD1 contribute to metabolic inflammation and insulin resistance. *Cell Rep.* (2017) 18:2415–26. doi: 10.1016/j.celrep.2017.02.027

14. Fernandez NJ, Kidney BA. Alkaline phosphatase: beyond the liver. *Vet Clin Pathol.* (2007) 36:223–33. doi: 10.1111/j.1939-165x.2007.tb00216.x

15. Seo MS, Shim JY, Lee YJ. Relationship between serum alkaline phosphatase level, C-reactive protein and leukocyte counts in adults aged 60 years or older. *Scand J Clin Lab Invest.* (2019) 79:233–7. doi: 10.1080/00365513.2019.1585567

16. Kim JH, Lee HS, Park HM, Lee YJ. Serum alkaline phosphatase level is positively associated with metabolic syndrome: a nationwide population-based study. *Clin Chim Acta*. (2020) 500:189–94. doi: 10.1016/j.cca.2019.10.015

17. Krishnamurthy VR, Baird BC, Wei G, Greene T, Raphael K, Beddhu S. Associations of serum alkaline phosphatase with metabolic syndrome and mortality. *Am J Med.* (2011) 124:566.e1–7. doi: 10.1016/j.amjmed.2010.11.030

18. Sukumaran M, Bloom WL. Influence of diet on serum alkaline phosphatase in rats and men. *Proc Soc Exp Biol Med*. (1953) 84:631–4. doi: 10.3181/00379727-84-20735 19. Domar U, Karpe F, Hamsten A, Stigbrand T, Olivecrona T. Human intestinal alkaline phosphatase--release to the blood is linked to lipid absorption, but removal from the blood is not linked to lipoprotein clearance. *Eur J Clin Investig.* (1993) 23:753–60. doi: 10.1111/j.1365-2362.1993.tb01296.x

20. Menahan LA, Sobocinski KA, Austin BP. Characterization of elevated plasma alkaline phosphatase activity in genetically obese mice. *Metabolism.* (1985) 34:272–7. doi: 10.1016/0026-0495(85)90012-5

21. Tuganbaev T, Mor U, Bashiardes S, Liwinski T, Nobs SP, Leshem A, et al. Diet diurnally regulates small intestinal microbiome-epithelial-immune homeostasis and enteritis. *Cell.* (2020) 182:1441–1459.e21. doi: 10.1016/j.cell.2020.08.027

22. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science*. (2018) 359:1376–83. doi: 10.1126/science.aar3318

23. Breznik JA, Ribeiro TA, Yeo E, Kennelly BKE, Wang X, Quin C, et al. Maternal adaptations in mouse lactation are vulnerable to diet-induced excess adiposity. *bioRxiv*. (2023) 547298. doi: 10.1101/2023.06.30.547298

24. Zhao L, Kwon MJ, Huang S, Lee JY, Fukase K, Inohara N, et al. Differential modulation of nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. *J Biol Chem.* (2007) 282:11618–28. doi: 10.1074/jbc.M608644200

25. Zhou YJ, Tang YS, Song YL, Li A, Zhou H, Li Y. Saturated fatty acid induces insulin resistance partially through nucleotide-binding oligomerization domain 1 signaling pathway in adipocytes. *Chin Med Sci J.* (2013) 28:211–7. doi: 10.1016/s1001-9294(14)60004-3

26. Rangan P, Choi I, Wei M, Navarrete G, Guen E, Brandhorst S, et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. *Cell Rep.* (2019) 26:2704–2719.e6. doi: 10.1016/j.celrep.2019.02.019

27. Boza JJ, Moennoz D, Vuichoud J, Jarret AR, Gaudard-de-Weck D, Fritsche R, et al. Food deprivation and refeeding influence growth, nutrient retention and functional recovery of rats. *J Nutr.* (1999) 129:1340–6. doi: 10.1093/jn/129.7.1340

28. Cavallari JF, Barra NG, Foley KP, Lee A, Duggan BM, Henriksbo BD, et al. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice. *Am J Physiol Endocrinol Metab.* (2020) 318:E579–85. doi: 10.1152/ajpendo.00033.2020